Brief: Regeneron Announces Strategic Collaboration With Parabilis Medicines To Advance Novel Antibody-Helicon Conjugates Across Multiple Therapeutic Areas
18/05/2026 12:01
May 18 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O: REGENERON ANNOUNCES STRATEGIC COLLABORATION WITH PARABILIS MEDICINES TO ADVANCE NOVEL ANTIBODY-HELICON™ CONJUGATES ACROSS MULTIPLE THERAPEUTIC AREAS REGENERON PHARMACEUTICALS INC: AGREEMENT PROVIDES FOR PARABILIS TO RECEIVE $125M FROM REGENERON REGENERON: DEAL INCLUDES ABOUT $2.2B IN ADDITIONAL POTENTIAL MILESTONE PAYMENTS PLUS TIERED ROYALTIES REGENERON PHARMACEUTICALS: UNDER TERMS, ADDITIONAL TARGETS MAY BE PURSUED UPON ADDITIONAL OPTION PAYMENTS FROM CO Source text: ID:nGNX5zPMMr Further company coverage: REGN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regeneron Pharmaceuticals
See all newsLilly, Regeneron selected for US program to review new manufacturing plants faster (updated)
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
Brief: Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities - CNBC
Brief: Cemdisiran Regulatory Submissions Accepted For Review By FDA And EMA For The Treatment Of Generalized Myasthenia Gravis (Gmg)
AbbVie sharpens immunology focus with $10.9 billion Apogee deal (updated)